A surreal illustration showing the connection between mental health and prostate cancer, representing the study's findings on depression and cancer progression.

Mind-Body Connection: Can Depression Fuel Prostate Cancer?

Jordan Keane monogram
Jordan Keane in Health & Wellness October 2026 • 4 min read.

"New research unveils how psychological stress triggers biological pathways that may accelerate prostate cancer growth and explores novel strategies for intervention."


Prostate cancer is a leading health concern for men worldwide. While genetics and lifestyle factors have long been recognized as key players, emerging research is shedding light on the unexpected influence of psychological well-being. Studies suggest a significant correlation between mental health and prostate cancer progression, urging both patients and healthcare providers to consider the mind-body connection in comprehensive cancer care.

Depression, a prevalent mental health disorder, can trigger a cascade of physiological changes within the body. Chronic stress and emotional distress have been shown to impact the immune system, hormonal balance, and even cellular growth. Understanding how these depression-related changes interact with cancer development is crucial for devising more effective treatment strategies.

Recent studies have revealed a specific pathway by which depression may fuel prostate cancer growth. This involves the increased secretion of neuropeptide Y, a molecule released under stress, which promotes the recruitment of myeloid cells, a type of immune cell, to the tumor site. These findings open new avenues for therapeutic intervention, targeting both the mental and physical aspects of the disease.

AI Search Multiple angles on this topic

From History to Patient Well-Being

The history of prostate cancer includes changing ideas about masculinity, sexuality, and disease in the modern scientific era. After World War II, academic medicine created new spaces for prostate-cancer care through the integration of predominantly male Veterans. A 2023 review further summarizes major developments in prostate-cancer diagnosis and treatment over the past 60 years, while recent research reports greater depression, anxiety, and fear of recurrence among patients diagnosed with metastatic disease.

How Does Depression Promote Prostate Cancer?

A surreal illustration showing the connection between mental health and prostate cancer, representing the study's findings on depression and cancer progression.

A new study published in "Clinical Cancer Research" has uncovered a concerning link between depression and prostate cancer. Researchers found that psychological stress can stimulate the secretion of neuropeptide Y (NPY), a signaling molecule that appears to promote cancer growth. This process involves a complex interplay between the nervous system, immune cells, and tumor cells.

The research team's experiments with mouse models revealed that stressed mice exhibited increased levels of NPY, which in turn recruited myeloid-derived suppressor cells (MDSCs) to the prostate tumor microenvironment. These MDSCs, instead of fighting the cancer, suppress the immune system's ability to attack the tumor, creating a favorable environment for cancer cells to thrive.

Here’s a breakdown of the key steps in this process:
  • Stress and NPY: Psychological stress triggers the release of norepinephrine (NE), a neurotransmitter, which then stimulates prostate cancer cells to secrete NPY.
  • Myeloid Cell Recruitment: NPY acts as a signal, attracting MDSCs to the tumor site.
  • Immune Suppression: Once at the tumor, MDSCs suppress the activity of T cells, crucial immune cells that would normally target and destroy cancer cells.
  • Cancer Growth: With the immune system suppressed, prostate cancer cells proliferate more readily, leading to accelerated tumor growth.
AI Search Multiple angles on this topic

Limits of the Evidence

Although one Oncogene study examines how depression may promote prostate-cancer invasion and metastasis through a sympathetic-cAMP-FAK signaling pathway, its source description states that the mechanisms linking depression and cancer outcomes remain unclear. A systematic review emphasizes the need to identify factors associated with mental well-being and to design and evaluate interventions before and after treatment. Treatment side effects, including erectile dysfunction, incontinence, and hot flashes, also represent important mental-health challenges, even as long-term survival continues to improve.

Cancer, Nerves, and Mental Health

Research on prostate-cancer biology has examined neuropeptide Y nerve density in treatment-resistant disease, reporting a comparison between patients who failed radiotherapy and controls treated only with radical prostatectomy. Separately, nationally representative data from the Medical Expenditure Panel Survey Household Component for 2017–2022 found that men with prostate cancer had mental-health outcomes comparable to men without cancer and more favorable outcomes than men with other malignancies. The reported proportion with suboptimal mental health differs slightly between the sources, with one reporting nearly 40% and another reporting over 40%, but both support continued psychosocial screening and support.

Further analyses of human prostate cancer samples revealed a similar pattern. Patients with higher scores for psychological depression also had increased levels of NPY and MDSCs in their tumors, suggesting that the findings in mice are relevant to human disease.

What Can You Do?

While the link between depression and prostate cancer may seem daunting, it also opens doors to new treatment strategies. The study suggests that targeting NPY signaling or blocking the recruitment of MDSCs could potentially slow down cancer progression in depressed patients. Additionally, managing mental health through therapy, medication, and lifestyle changes may offer a holistic approach to cancer care.

AI Search Multiple angles on this topic

A Cautious Synthesis

Current evidence identifies prognostic factors associated with mental-well-being outcomes in men with prostate cancer and may help identify higher-risk groups for preventive and therapeutic support. However, the evidence is heterogeneous, and the cited review calls for further research into less conclusive factors and outcomes. The available findings therefore support attention to mental health without establishing a simple, settled causal pathway from depression to prostate cancer.

Living With Advanced Disease

An advanced prostate-cancer diagnosis can alter a person’s relationships and plans for the future. It can also affect a patient’s sense of self. These changes show why mental health remains an important consideration as people navigate advanced disease.

The Lived Experience

Qualitative research on men who underwent radical prostate-cancer treatment identified an uncertain future and social planning as key themes affecting mental well-being. A 2022 study notes that quality of life in survivorship includes mental and social well-being, while also describing the limited global evaluation of psychosocial challenges after treatment. A 2025 systematic review similarly aims to synthesize patients’ lived experiences and coping strategies to support tiered psychosocial services.

Depression estimates across prostate-cancer treatment stages

  • 17.27%Depression prevalence was 17.27% before treatment, 14.70% during treatment, and 18.44% after treatment. These pooled estimates come from studies whose methods varied enough to prevent statistical pooling of prevalence rates in another review.[1] [2]

How risk, treatment, and outcome findings compare

Among patients with metastatic prostate cancer, depression was associated with higher mortality risk, but the depressed and non-depressed groups differed in stage distribution. The data also concern depression diagnosed after cancer, so they do not establish that depression caused the survival difference.[3]

A review of cancer research describes the overall evidence that stress directly affects survival as weak, and notes that stress-related behaviors could provide an indirect route to cancer risk. Laboratory findings on norepinephrine and cancer processes therefore do not by themselves establish a direct effect on patient outcomes.[4]

What remains unresolved about depression and prostate cancer

  • Would the association between depression and mortality remain if depressed and non-depressed groups had more comparable disease stages?[3]
  • How much of the depression seen around treatment reflects treatment itself, disease burden, or other factors? The reported association with androgen-deprivation therapy and the observation that advanced disease and treatment burden are depression risk factors leave these explanations intertwined.[5] [6]

Sources

  1. Depression and anxiety in prostate cancer: a systematic review and meta-analysis of prevalence rates (pmc.ncbi.nlm.nih.gov)
  2. Examining the prevalence and predictors of anxiety and depression across treatment stages in prostate cancer: a systematic review (pmc.ncbi.nlm.nih.gov)
  3. Depression Negatively Impacts Survival of Patients with Metastatic Prostate Cancer (pmc.ncbi.nlm.nih.gov)
  4. Stress and Cancer - NCIFacebookFollow on XInstagramYoutubeLinkedin (www.cancer.gov)
  5. Development of depression in patients using androgen deprivation therapy: A systemic review and meta-analysis. (onlinelibrary.wiley.com)
  6. Anxiety and depression in adult cancer patients: ESMO Clinical Practice Guideline - PMC Lock (pmc.ncbi.nlm.nih.gov)

About this Article -

Written with AI assistance from published research, and reviewed by the Mystum team. See our About page for more information.

Everything You Need To Know

1

How does feeling depressed affect prostate cancer?

Psychological depression can influence prostate cancer progression through a specific biological pathway. Stress triggers the release of norepinephrine, which stimulates prostate cancer cells to secrete neuropeptide Y (NPY). NPY then recruits myeloid-derived suppressor cells (MDSCs) to the tumor site. These MDSCs suppress the activity of T cells, which are crucial immune cells that normally target and destroy cancer cells. This immune suppression creates a favorable environment for prostate cancer cells to proliferate, leading to accelerated tumor growth.

2

What is Neuropeptide Y (NPY), and why is it important in prostate cancer?

Neuropeptide Y (NPY) is a signaling molecule released under stress. In the context of prostate cancer, NPY plays a significant role by attracting myeloid-derived suppressor cells (MDSCs) to the tumor site. This recruitment suppresses the immune system's ability to attack the tumor, promoting cancer growth. High levels of NPY in human prostate cancer samples correlate with increased psychological depression scores, suggesting its importance in the connection between mental health and cancer progression.

3

What are Myeloid-Derived Suppressor Cells (MDSCs), and how do they relate to prostate cancer?

Myeloid-derived suppressor cells (MDSCs) are a type of immune cell. Instead of fighting the cancer, they suppress the activity of T cells. T cells are crucial immune cells that would normally target and destroy cancer cells. By suppressing T cell activity, MDSCs create a favorable environment for cancer cells to thrive, leading to accelerated tumor growth. This process highlights the complex interplay between the nervous system, immune cells, and tumor cells in the progression of prostate cancer.

4

Based on these findings, what actions can someone take to address the link between depression and prostate cancer?

To potentially slow down cancer progression, it is suggested that targeting neuropeptide Y (NPY) signaling or blocking the recruitment of myeloid-derived suppressor cells (MDSCs) could be effective. Simultaneously, managing mental health through therapy, medication, and lifestyle changes may offer a holistic approach to cancer care. These strategies address both the mental and physical aspects of the disease, aiming to disrupt the pathway by which depression fuels prostate cancer growth.

5

Does this research mean that depression is the only thing that causes prostate cancer to get worse?

The research indicates a link between mental health and prostate cancer, but genetics and lifestyle factors still play key roles. While the study focuses on the impact of psychological stress and depression on cancer progression, it doesn't negate the significance of genetic predispositions, diet, exercise, and other lifestyle choices in the development and management of prostate cancer. Addressing both mental and physical well-being is essential for comprehensive cancer care.

Newsletter Subscribe

Subscribe to get the latest articles and insights directly in your inbox.